Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: The Safe, Simple Transitions (SST) studyRoger M. Mills, Peter Wildgoose, Richard Berkowitz et al.|Thrombosis Research|2012Cited by 12
IMPACT OF COMORBIDITIES ON TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATIONJiyoon Choi, Winnie W. Nelson, Peter Wildgoose et al.|Journal of the American College of Cardiology|2012Cited by 4
Initiating thromboprophylaxis with low molecular weight heparin and transitioning to oral rivaroxabanRoger M. Mills, Peter Wildgoose, Lisa K. Jennings et al.|European Journal of Hospital Pharmacy|2012Cited by 0
PCV8 Impct of Comorbidities on Time in Therapeutic Range in Patients with Nonvalvular Atrial FibrillationJeongeun Choi, Woodrow Nelson, C.V. Damaraju et al.|Value in Health|2012Cited by 0